CLU and prostate carcinoma: Epigenetic regulation of CLU has also been observed in multiple cell types, including prostate cancer cells, neural cells, and retinal pigment epithelial cells [334–336], suggesting that CLU expression is epigenetically modulated by factors such as aging, stress, and inflammation, known contributors to AD pathology.